Benefits
Cardiovascular use in TCM and Chinese hospital practice
Most-used TCM herb for cardiovascular conditions over 2,000 years. Widely used in Chinese hospitals as IV preparations (Danhong, Salvianolate, Compound Danshen) for acute angina, MI, stroke. Hundreds of Chinese RCTs reported but methodological quality concerns: poor blinding, short duration, weak control conditions, language barriers. Mechanism robust (vasodilation, antiplatelet, antioxidant); clinical translation to oral Western use has been mixed.
Compound Danshen Dropping Pill (CDDP) for stable angina
CDDP — combination of Salvia miltiorrhiza + Panax notoginseng + Borneol — has multiple Chinese RCTs for stable angina pectoris suggesting symptomatic improvement. 2025 review (PMC12014028) summarized RCT evidence with general support for symptom relief, though methodological concerns persist. NOT widely available/marketed in Western markets but established as multi-million-dollar Chinese pharmaceutical product.
NEGATIVE Western trial in hypertension/dyslipidemia (Van Poppel 2015)
Van Poppel 2015 (PMC4508048, PLoS One) Dutch double-blind randomized crossover trial used Salvia miltiorrhiza root water-extract (3 g/day for 4 weeks) in patients with hypertension and hyperlipidemia. RESULT: NO beneficial effect on cardiovascular risk factors — no significant reduction in BP, lipids, or other markers vs placebo. Important Western counterevidence to enthusiastic Chinese trial results — suggests effects may depend on preparation type, population, formulation, or other factors not isolated in monotherapy oral testing.
In vitro and animal mechanistic support
Tanshinone IIA and salvianolic acids robustly demonstrate: ACE inhibition, vasodilation, antiplatelet activity, anti-inflammatory effects, antioxidant capacity, anticoagulant effects, mitochondrial protection, free radical scavenging. Mechanistic basis is strong; clinical translation is the gap. Used as research compound in cardiovascular preclinical models extensively.
Antiplatelet activity (relevant to traditional 'blood-moving' uses)
Tanshinones inhibit platelet aggregation in vitro and in animal models — mechanistic basis for traditional 'blood-moving' (huo xue) classification. Clinically important because this mechanism explains the documented warfarin INR elevation interactions — a real concern for safety in patients on anticoagulants.
Mechanism of action
ACE inhibition and angiotensin II reduction
Salvia miltiorrhiza components inhibit angiotensin converting enzyme (ACE), reducing angiotensin II levels and indirectly affecting atrial natriuretic peptide. Mechanism comparable to (but weaker than) pharmaceutical ACE inhibitors. Provides theoretical basis for cardiovascular protection — though oral monotherapy effect size in Western trials has been modest at best.
Vasodilation via nitric oxide and calcium channel modulation
Tanshinones produce vasodilation via multiple mechanisms: NO synthesis enhancement, calcium channel modulation, smooth muscle relaxation. Improves coronary blood flow in animal models and in vitro. Underlies traditional applications for chest pain, stroke recovery, peripheral vascular conditions.
Antiplatelet effects via thromboxane reduction
Tanshinones inhibit platelet aggregation by reducing thromboxane A2 production and modulating COX-1 pathway. Mechanism comparable to aspirin but typically weaker. Clinically important for both traditional 'blood-moving' indication AND for warfarin interaction concerns.
Antioxidant and anti-inflammatory pleiotropic effects
Salvianolic acids increase SOD, catalase, GPx, GSH levels; reduce lipid peroxidation and inflammatory cytokines. Combined antioxidant + anti-inflammatory effects relevant to ischemia-reperfusion injury (the rationale for IV use in acute MI/stroke in Chinese hospitals). Mechanism strong; standalone oral consumer product effect size unclear.
Clinical trials
Randomized double-blind cross-over trial (van Poppel PCM, Breedveld P, Abbink EJ, Roelofs H, van Heerde W, Smits P, Lin W, Tan AHA, Russel FG, Donders R, Tack CJ, Rongen GA 2015, PLoS One 10(6):e0128695, doi:10.1371/journal.pone.0128695). NCT01563770. PMC4508048.
Patients with hypertension and hyperlipidemia (ages 40-70). Randomized to 3 capsules of 500 mg Salvia miltiorrhiza extract twice daily (3 g/day) OR placebo for 4 weeks each in crossover design. Endpoints: lipid profile, BP, endothelial function, oxidative stress, inflammation, hemostasis, insulin sensitivity.
NO BENEFICIAL EFFECT on cardiovascular risk factors. No significant changes in lipid profile, BP, endothelial function, or other CV risk markers vs placebo. Authors concluded: 'Salvia miltiorrhiza root water-extract has no beneficial effect on cardiovascular risk factors.' Important Western counterevidence to Chinese trials. Authors noted: quality of Chinese RCTs of Danshen is poor; not easily accessible to Western physicians as most published in Chinese — explanation for evidence base disconnect.
Review (Wei 2025, related publications, PMC12014028).
Reviews of multiple Chinese RCTs of Compound Danshen Dropping Pill (Salvia miltiorrhiza + Panax notoginseng + Borneol) for stable angina pectoris. Comparator: standard pharmacological treatments (nitrates, beta-blockers, calcium channel blockers).
CDDP demonstrated symptomatic improvement in angina pectoris in multiple Chinese RCTs — though most have methodological limitations (blinding concerns, short duration, weak controls). Establishes clinical use case for combination Danshen formulas rather than monotherapy. Notable: traditional Chinese use is almost ALWAYS in combination — Western monotherapy testing may not reflect optimal use.
Comprehensive pharmacology review (Adams JD, Wang R, Yang J, Lien EJ 2006, Chin Med 1:3, doi:10.1186/1749-8546-1-3).
Review of preclinical and clinical examinations of Salvia miltiorrhiza and tanshinones in ischemic conditions including angina, heart attack, stroke.
Documented robust preclinical evidence for: ACE inhibition, vasodilation, antiplatelet activity, anti-inflammatory effects, antioxidant capacity. Clinical evidence assessed across preparation types, doses, blinding, controls. Authors noted methodological limitations of available trials and emphasized need for more rigorous Western-standard RCTs. Established the central tension in danshen evidence: strong mechanism + traditional use vs limited rigorous modern trial validation.
About this ingredient
Salvia miltiorrhiza Bunge (Danshen, Dan Shen, 丹参, 'red sage') is a perennial flowering plant of the Lamiaceae family native to China, Mongolia, Japan. The dried root (red color, hence 'dan' meaning red) has been used in TCM for over 2,000 years primarily for cardiovascular conditions: angina pectoris, myocardial infarction, stroke, atherosclerosis. Considered one of the most important 'blood-moving' (huo xue hua yu) herbs in Chinese medicine.
PHYTOCHEMISTRY divided into TWO categories: (1) LIPOPHILIC TANSHINONES (red-colored diterpenoid quinones, soluble in alcohol/lipid): tanshinone I, tanshinone IIA (most clinically studied), tanshinone IIB, cryptotanshinone, dihydrotanshinone. (2) HYDROPHILIC SALVIANOLIC ACIDS (water-soluble phenolic acids): salvianolic acid A and B, danshensu (2-hydroxy-4-catecholbutyric acid — note: in modern Chinese literature 'danshensu' often refers to tanshinone IIA), rosmarinic acid. Other components: protocatechuic aldehyde, ferulic acid, baicalin (related compound).
Salvianolic acid B is the major hydrophilic component (often the standardization target). PHARMACEUTICAL PREPARATIONS in China: oral extracts; INTRAVENOUS preparations (Danhong injection, Salvianolate injection, Compound Danshen injection, Sodium Tanshinone IIA Sulfonate); ORAL CHINESE BLOCKBUSTER: Compound Danshen Dropping Pill (CDDP — Salvia + Panax notoginseng + Borneol). MARKETED IN CHINESE PHARMACOPOEIA.
EVIDENCE: 2/5 reflects: (1) HUNDREDS of Chinese RCTs reported with positive cardiovascular outcomes, BUT methodological quality concerns + language/access barriers + publication bias suspected, (2) PIVOTAL Van Poppel 2015 PMC4508048 Western negative crossover trial in hypertension/dyslipidemia, (3) extensive preclinical mechanism evidence (ACE inhibition, vasodilation, antiplatelet, antioxidant), (4) Adams 2006 review documenting both strong preclinical signal and weak rigorous human trial base, (5) widespread clinical use in Chinese hospitals (especially IV) but limited Western adoption due to evidence quality issues. Complex evidence picture: traditional reputation + Chinese clinical use vs Western rigorous testing concerns. SAFETY: Warfarin interaction is THE major safety concern; pregnancy avoid.
Best positioned as: (a) component of TCM combination protocols under TCM practitioner guidance (especially CDDP for stable angina), (b) NOT recommended as monotherapy for hypertension/dyslipidemia based on negative Western RCT evidence, (c) STRICTLY AVOID with warfarin or other anticoagulants, (d) IV preparations (Danhong, etc.) are clinician-administered in Chinese hospitals — not consumer products. Honest framing: profoundly important traditional cardiovascular herb with substantial Chinese clinical use but Western rigorous evidence is limited and one major Western trial was negative — important to acknowledge the evidence gap rather than rely solely on traditional reputation.